The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 24, 2012
Filed:
Jul. 10, 2006
Werner Breitenstein, Basel, CH;
Claus Erhardt, Lörrach, DE;
Juergen Klaus Maibaum, Weil-Haltingen, DE;
Nils Ostermann, Binzen, DE;
Juerg Zimmermann, Reinach, CH;
Keiichi Masuya, Bottmingen, CH;
Kazuhide Konishi, Ibaraki, JP;
Fumiaki Yokokawa, Ibaraki, JP;
Takanori Kanazawa, Ibaraki, JP;
Edgar Jacoby, Basel, CH;
Andreas Marzinzik, Weil, DE;
Philipp Grosche, Inzlingen, DE;
Shimpei Kawakami, Ibaraki, JP;
Werner Breitenstein, Basel, CH;
Claus Erhardt, Lörrach, DE;
Juergen Klaus Maibaum, Weil-Haltingen, DE;
Nils Ostermann, Binzen, DE;
Juerg Zimmermann, Reinach, CH;
Keiichi Masuya, Bottmingen, CH;
Kazuhide Konishi, Ibaraki, JP;
Fumiaki Yokokawa, Ibaraki, JP;
Takanori Kanazawa, Ibaraki, JP;
Edgar Jacoby, Basel, CH;
Andreas Marzinzik, Weil, DE;
Philipp Grosche, Inzlingen, DE;
Shimpei Kawakami, Ibaraki, JP;
Novartis AG, Basel, CH;
Abstract
The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.